AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Silence Therapeutics plc

Declaration of Voting Results & Voting Rights Announcements Jun 26, 2013

33536_rns_2013-06-26_6496152c-b9af-41b7-8ad3-c679189589ea.html

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8547H

Silence Therapeutics PLC

26 June 2013

Silence Therapeutics plc ("Silence" or the "Company")

BOARD CHANGE

26 June 2013

Resignation of director

David Mack, non-executive director, is stepping down from the board of the Company ahead of today's annual general meeting. Based in San Francisco, he has been a director of the Company since the acquisition in 2010 of Intradigm Corporation. Alta Partners, where he is a director, disposed of its holding in Silence in November 2012. The board would like to express their thanks and appreciation to David for his work on the board of the Company, and wish him every success in his future endeavours.

For further information please contact:

Silence Therapeutics

Ali Mortazavi, chief executive/Timothy Freeborn, finance director +44 (0)333 988 0140

[email protected]

[email protected]

N+1 Singer

Shaun Dobson/Jenny Wyllie

+44 20 7496 3000

[email protected]

[email protected]

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAPGUAUQUPWGRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.